ITMI20022394A1 - Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. - Google Patents

Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.

Info

Publication number
ITMI20022394A1
ITMI20022394A1 ITMI20022394A ITMI20022394A1 IT MI20022394 A1 ITMI20022394 A1 IT MI20022394A1 IT MI20022394 A ITMI20022394 A IT MI20022394A IT MI20022394 A1 ITMI20022394 A1 IT MI20022394A1
Authority
IT
Italy
Prior art keywords
pharmaceutical formulations
activity
triodothyronin
thyroimimetic
sulphate
Prior art date
Application number
Other languages
English (en)
Inventor
Aldo Pinchera
Ferruccio Santini
Original Assignee
Bracco Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Spa filed Critical Bracco Spa
Priority to ITMI20022394 priority Critical patent/ITMI20022394A1/it
Priority to SI200330550T priority patent/SI1560575T1/sl
Priority to DE2003608718 priority patent/DE60308718T2/de
Priority to AT03767529T priority patent/ATE340570T1/de
Priority to PCT/EP2003/012584 priority patent/WO2004043452A1/en
Priority to CNA2008101357627A priority patent/CN101406467A/zh
Priority to PT03767529T priority patent/PT1560575E/pt
Priority to US10/532,447 priority patent/US9012438B2/en
Priority to DK03767529T priority patent/DK1560575T3/da
Priority to JP2004550983A priority patent/JP5301074B2/ja
Priority to AU2003292006A priority patent/AU2003292006A1/en
Priority to CNA2003801030574A priority patent/CN1711079A/zh
Priority to ES03767529T priority patent/ES2273045T3/es
Priority to EP20060117480 priority patent/EP1767202A1/en
Priority to EP03767529A priority patent/EP1560575B1/en
Publication of ITMI20022394A1 publication Critical patent/ITMI20022394A1/it
Priority to CY061101656T priority patent/CY1107312T1/el
Priority to JP2010288189A priority patent/JP2011102306A/ja
Priority to US13/083,047 priority patent/US20110245342A1/en
Priority to US14/110,237 priority patent/US9890116B2/en
Priority to US13/755,279 priority patent/US9044441B2/en
Priority to US13/916,710 priority patent/US9468619B2/en
Priority to US15/271,355 priority patent/US10238615B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G01N33/561—Immunoelectrophoresis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/78—Thyroid gland hormones, e.g. T3, T4, TBH, TBG or their receptors
ITMI20022394 2002-11-13 2002-11-13 Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. ITMI20022394A1 (it)

Priority Applications (22)

Application Number Priority Date Filing Date Title
ITMI20022394 ITMI20022394A1 (it) 2002-11-13 2002-11-13 Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
CNA2003801030574A CN1711079A (zh) 2002-11-13 2003-11-11 作为拟甲状腺素剂的硫酸3,5,3′－三碘甲状腺原氨酸及其药用制剂
ES03767529T ES2273045T3 (es) 2002-11-13 2003-11-11 Sulfato de 3,5,3, -triyodotironina como agente tiromimetico y formulaciones farmaceuticas.
DE2003608718 DE60308718T2 (de) 2002-11-13 2003-11-11 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff und pharmaceutische formulierungen davon
PCT/EP2003/012584 WO2004043452A1 (en) 2002-11-13 2003-11-11 3,5,3’-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
CNA2008101357627A CN101406467A (zh) 2002-11-13 2003-11-11 作为拟甲状腺素剂的硫酸3,5,3’-三碘甲状腺原氨酸及其药用制剂
PT03767529T PT1560575E (pt) 2002-11-13 2003-11-11 Sulfato de triiodotironina como agente tiromimético e as suas formulações farmacêuticas
US10/532,447 US9012438B2 (en) 2002-11-13 2003-11-11 3,5,3′ -triiodothronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
DK03767529T DK1560575T3 (da) 2002-11-13 2003-11-11 3,5,3'-triiodthyroninsulfat som thyromimetisk middel og farmaceutiske formuleringer deraf
EP20060117480 EP1767202A1 (en) 2002-11-13 2003-11-11 3,5,3'-Triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
AU2003292006A AU2003292006A1 (en) 2002-11-13 2003-11-11 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
SI200330550T SI1560575T1 (sl) 2002-11-13 2003-11-11 3,5,3'-trijodotironin-sulfat kot tiromimeticna ucinkovina in njegove farmacevtske oblike
AT03767529T ATE340570T1 (de) 2002-11-13 2003-11-11 3,5,3'-triiodothyronin sulfat als thyromimetischer wirkstoff and pharmaceutische formulatierungen davon
JP2004550983A JP5301074B2 (ja) 2002-11-13 2003-11-11 甲状腺ホルモン薬剤としての３，５，３’−トリヨードチロニン硫酸塩及びその製薬調剤
EP03767529A EP1560575B1 (en) 2002-11-13 2003-11-11 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
CY061101656T CY1107312T1 (el) 2002-11-13 2006-11-14 Θειικη 3,5,3’-τριιωδοθυρονινη σαν θυρεοειδο-μιμητικος παραγοντας και φαρμακευτικα σκευασματα της
JP2010288189A JP2011102306A (ja) 2002-11-13 2010-12-24 甲状腺ホルモン薬剤としての３，５，３’−トリヨードチロニン硫酸塩及びその製薬調剤
US13/083,047 US20110245342A1 (en) 2002-11-13 2011-04-08 3,5,3'-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
US14/110,237 US9890116B2 (en) 2002-11-13 2012-04-05 Process for the preparation of a sulfated derivative of 3,5-diiodo-O-[3-iodophenyl]-L-tyrosine
US13/755,279 US9044441B2 (en) 2002-11-13 2013-01-31 3,5,3′-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
US13/916,710 US9468619B2 (en) 2002-11-13 2013-06-13 3,5,3′-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof
US15/271,355 US10238615B2 (en) 2002-11-13 2016-09-21 3,5,3′-triiodothyronine sulfate as thyromimetic agent and pharmaceutical formulations thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI20022394 ITMI20022394A1 (it) 2002-11-13 2002-11-13 Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.

Publications (1)

Publication Number Publication Date
ITMI20022394A1 true ITMI20022394A1 (it) 2004-05-14

Family

ID=32310157

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI20022394 ITMI20022394A1 (it) 2002-11-13 2002-11-13 Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.

Country Status (13)

Country Link
US (5) US9012438B2 (it)
EP (2) EP1767202A1 (it)
JP (2) JP5301074B2 (it)
CN (2) CN101406467A (it)
AT (1) ATE340570T1 (it)
AU (1) AU2003292006A1 (it)
CY (1) CY1107312T1 (it)
DE (1) DE60308718T2 (it)
DK (1) DK1560575T3 (it)
ES (1) ES2273045T3 (it)
IT (1) ITMI20022394A1 (it)
PT (1) PT1560575E (it)
WO (1) WO2004043452A1 (it)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) * 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
GB0525461D0 (en) 2005-12-15 2006-01-25 Archimedes Dev Ltd Pharmaceutical compositions
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CN103534232A (zh) * 2011-04-08 2014-01-22 伯拉考成像股份公司 用于制备3,5-二碘-o-[3-碘苯基]-l-酪氨酸的硫酸化衍生物的方法
CN102507919A (zh) * 2011-11-08 2012-06-20 江苏省原子医学研究所 一种标记3,3’-二碘甲腺氨酸硫酸化物的方法及检测试剂盒
EP3140316A1 (en) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
ES2706493T3 (es) 2014-06-18 2019-03-29 Thetis Pharmaceuticals Llc Complejos de aminoácidos minerales de agentes activos
US10130719B2 (en) 2016-06-03 2018-11-20 Thetis Pharmaceuticals Llc Compositions and methods relating to salts of specialized pro-resolving mediators
JP6968603B2 (ja) * 2017-07-10 2021-11-17 キヤノン株式会社 画像形成装置、画像形成方法、プログラム
BR112021000443A2 (pt) * 2018-07-13 2021-04-06 Aegirbio Ab Sensor e método para quantificação de um hormônio da tireoide, métodos para diagnosticar e para monitorar um distúrbio relacionado com a tireoide e para fabricar um sensor, uso do sensor, e, dispositivo portátil para quantificação e/ou monitoramento de um hormônio da tireoide

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2993928A (en) 1957-01-15 1961-07-25 Glaxo Lab Ltd Preparation of triiodothyronine
US2970165A (en) 1957-10-01 1961-01-31 Warner Lambert Pharmaceutical Sulfate compounds
US3313839A (en) 1963-07-01 1967-04-11 Gen Aniline & Film Corp Preparation of sulfate esters by the reaction of chlorosulfonic acid with alkoxylated alkyl phenols
US4031622A (en) * 1975-10-28 1977-06-28 Wells Manufacturing Corporation Portable power driven implement
US4254095A (en) * 1978-04-27 1981-03-03 Research Corporation Radioimmunoassay for erythropoietin
JPH07116031B2 (ja) 1986-09-24 1995-12-13 株式会社アドバンス 制癌剤
US5116828A (en) * 1989-10-26 1992-05-26 Nippon Zoki Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of osteoporosis
US5158978A (en) 1990-02-05 1992-10-27 British Technology Group (U.S.A.) Thyroid hormone treatment of acute cardiovascular compromise
ATE124258T1 (de) 1990-02-05 1995-07-15 British Tech Group Usa Schilddrüsenhormone zur kardialen behandlung.
US5272078A (en) * 1991-01-29 1993-12-21 Brigham And Women's Hospital CDNA encoding the type I iodothyronine 5'deiodinase
US6498037B1 (en) 1991-03-04 2002-12-24 Bayer Corporation Method of handling reagents in a random access protocol
US5225204A (en) 1991-11-05 1993-07-06 Chen Jivn Ren Stable dosage of levothyroxine sodium and process of production
DE69224809T2 (de) 1991-12-30 1998-07-09 Akzo Nobel Nv Thyroaktive Zusammensetzung mit kontrollierter Freigabe
KR950010051Y1 (ko) 1993-10-15 1995-11-25 이해섭 휴대용 절첩테이블
GB9401892D0 (en) 1994-02-01 1994-03-30 Boots Co Plc Therapeutic agents
DE19541128C2 (de) 1995-10-27 1997-11-27 Henning Berlin Gmbh & Co Stabilisierte schilddrüsenhormonhaltige Arzneimittel
ES2224184T3 (es) 1995-11-14 2005-03-01 ABBOTT GMBH & CO. KG Preparaciones estabilizadas de hormonas tiroideas y metodos para su fabricacion.
AU2679899A (en) 1998-02-18 1999-09-06 Dade Behring Inc. Chemiluminescent compositions for use in detection of multiple analytes
DE19821625C1 (de) 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
US6599942B1 (en) * 1999-03-29 2003-07-29 Novartis Ag Thyromimetic organic compounds
US6740680B1 (en) * 1999-04-26 2004-05-25 Becton Pharma, Inc. Pharmaceutical compositions to tetrac and methods of use thereof
US6664291B2 (en) * 2000-03-31 2003-12-16 Pfizer, Inc. Malonamic acids and derivatives thereof as thyroid receptor ligands
AU2001278034A1 (en) * 2000-07-26 2002-02-05 Bio-Diagnostics Inc. Method for diagnosing thyroid conditions and for monitoring thyroxine therapy
US7163918B2 (en) * 2000-08-22 2007-01-16 New River Pharmaceuticals Inc. Iodothyronine compositions
US6979462B1 (en) 2000-10-03 2005-12-27 Mutual Pharmaceutical Co., Inc. Stabilization of solid drug formulations
US6855333B1 (en) 2000-10-03 2005-02-15 Mutual Pharmaceutical Co., Inc. Stabilization of solid thyroid drug formulations
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
CA2438641A1 (en) 2001-02-15 2002-08-22 King Pharmaceuticals, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030224047A1 (en) 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
ITMI20011401A1 (it) 2001-07-02 2003-01-02 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei
DE10136615A1 (de) 2001-07-17 2003-02-06 Berlin Chemie Ag Schilddrüsentherapeutika
US20030195253A1 (en) 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030099699A1 (en) 2001-11-13 2003-05-29 Hanshew Dwight D. Storage stable thyroxine active drug formulations and methods for their production
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
ITMI20110713A1 (it) 2011-04-29 2012-10-30 Bracco Imaging Spa Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina
ITMI20022777A1 (it) 2002-12-27 2004-06-28 Altergon Sa Formulazioni farmaceutiche per ormoni tiroidei e procedimenti per il loro ottenimento.
US20040156893A1 (en) 2003-02-11 2004-08-12 Irwin Klein Method for treating hypothyroidism
US8293272B2 (en) 2003-05-02 2012-10-23 Globopharm Pharmazeutische Produktions-Und Handelsgesellschaft M.B.H. Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts
PT1622587E (pt) 2003-05-02 2010-07-07 Globopharm Pharmazeutische Pro Preparaã†o farmac—utica sëlida contendo sais de levotiroxina e/ou liotironina
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
DE14172396T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
CA2653262A1 (en) 2006-05-26 2007-12-06 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted carboxylic acid compounds
EP1958617B1 (en) 2007-02-14 2010-09-08 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing quetiapine fumarate
AU2008240374A1 (en) 2007-04-23 2008-10-30 Diurnal Limited Sustained release
EP1992341A1 (en) 2007-05-16 2008-11-19 Université Joseph Fourier New pharmaceutical compositions comprising a thyroid hormon and their therapeutic use
WO2008140459A1 (en) 2007-05-16 2008-11-20 Fmc Corporation Solid form
FR2931359B1 (fr) 2008-05-20 2012-12-21 Menvielle Bourg Fabienne Joanny Utilisation d'une matrice pour administration orale de magnesium a liberation prolongee, et composition contenant cette matrice
RU2011144145A (ru) 2009-04-01 2013-05-10 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
CN102259831A (zh) 2010-05-27 2011-11-30 清华大学 三维纳米结构阵列

Also Published As

Publication number Publication date
CN101406467A (zh) 2009-04-15
DE60308718D1 (de) 2006-11-09
US9012438B2 (en) 2015-04-21
ES2273045T3 (es) 2007-05-01
CY1107312T1 (el) 2012-11-21
JP5301074B2 (ja) 2013-09-25
DK1560575T3 (da) 2007-01-29
JP2006508956A (ja) 2006-03-16
CN1711079A (zh) 2005-12-21
AU2003292006A1 (en) 2004-06-03
US20170007563A1 (en) 2017-01-12
US9468619B2 (en) 2016-10-18
EP1767202A1 (en) 2007-03-28
US20110245342A1 (en) 2011-10-06
EP1560575B1 (en) 2006-09-27
US20130281536A1 (en) 2013-10-24
US9044441B2 (en) 2015-06-02
EP1560575A1 (en) 2005-08-10
JP2011102306A (ja) 2011-05-26
US20050272816A1 (en) 2005-12-08
DE60308718T2 (de) 2007-08-02
ATE340570T1 (de) 2006-10-15
US20130146502A1 (en) 2013-06-13
PT1560575E (pt) 2007-01-31
WO2004043452A1 (en) 2004-05-27
US10238615B2 (en) 2019-03-26

Similar Documents

Publication Publication Date Title
CY1107312T1 (el) Θειικη 3,5,3’-τριιωδοθυρονινη σαν θυρεοειδο-μιμητικος παραγοντας και φαρμακευτικα σκευασματα της
ECSP045081A (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados
DE69925133D1 (de) Pyrrolobenzodiazepine
CY1111867T1 (el) Ενωση ενεργοποιησης ppar και φαρμακευτικη συνθεση που περιεχει αυτη
TR200200706T2 (tr) Nöropatik ağrı tedavisi için retigabin kullanımı.
DE602005023185D1 (de) Prodrugs mit neuen biospaltbaren verbindern
ATE514418T1 (de) Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan
CY1112738T1 (el) Μια συνδυασμενη συνθεση που περιεχει ιβουπροφαινη και παρακεταμολη
NO2011018I1 (no) Eribulin og farmasøytisk akseptable salter derav
DE50005529D1 (de) Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ES2421948T3 (es) Compuestos y composiciones para suministrar agentes activos
BR0314058A (pt) Composições para cuidados pessoais a base de álcool ramificado
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
PA8553201A1 (es) Formulaciones en combinacion de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilizacion
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
BR0011845A (pt) Complexo farmacêutico
CY1107346T1 (el) Φαρμακευτικη συνθεση για την ενδοκυτταρια οξινιση με cis-ουροκανικο οξυ
ATE270551T1 (de) Kombinationspräparat aus 2-methylthiazolidin-2,4- dicarbonsäure und paracetamol
BRPI0415428A (pt) formulações terapêuticas
ITMI20030827A1 (it) Composizione farmaceutica contenente l'associazione levodopa/carbidopa.
AR030945A1 (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
ITMI20020872A1 (it) Derivati dell'iperforina loro uso e formulazioni che li contengono
BR0213463A (pt) Composições farmacêuticas contendo macrólidos
BR0306869A (pt) Composição farmacêutica orodispersìvel de piribedila
ITFI20030256A1 (it) Dispositivo per l'eliminazione dell'anidride carbonica